News
Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...
19h
Clinical Trials Arena on MSNDaiichi announces first subject dosing in Enhertu trial for endometrial cancerThe study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...
TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...
A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a ...
A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a ...
A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...
Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...
The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer. A live question and answer session will follow the formal presentations. Date: Tuesday, June 17, 2025 Time: 12 p ...
Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...
5don MSN
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...
Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results